[Cancer chemotherapy with special reference to pharmacokinetics of nitrosoureas].
This paper provides an overview of cancer chemotherapy with special reference to the pharmacokinetics of the nitrosoureas. At physiological PH, the chloroethylnitrosoureas can be decomposed into an isocyanate and 2-chloroethyl diazene hydroxide. Therefore, it is clear that they have both alkylation and carbamoylation actions. In addition to the spontaneous chemical dissociation, the nitrosoureas can be metabolized by liver microsomal enzymes to more polar hydroxylated products, and certain nitrosoureas can be denitrosated by these enzymes to the parent urea. Since the lipid-soluble nitrosoureas and some of the water-soluble nitrosoureas such as ACNU and MCNU demonstrated to cross the blood-brain barrier, they have been used in the treatment of primary brain tumors and tumors and tumors of metastatic origin. It has been demonstrated from the results of our study and other reports that the alkylation of DNA by ACNU progresses more slowly as compared with that of other alkylating agents. This is an important finding in relation to the appearance of delayed myelosuppression of the nitrosoureas and in the design of dose schedules of these agents. The major clinical emphasis has been directed towards the more active chloroethylnitrosoureas with reduced myelosuppression, and attempts are now made for this purpose. Unfortunately, the results of phase I and II trials of the newly developed nitrosoureas suggest that these agents produce delayed and cumulative bone marrow toxicity. Antitumor activity of the nitrosoureas is frequestly observed in chronic myelocytic leukemia, malignant lymphoma, brain tumors and small cell carcinoma of the lung, and less frequently in gastrointestinal carcinoma, multiple myeloma and malignant melanoma. In order to enhance clinical effects of the nitrosoureas, further investigation of the design in therapeutic schedules on the basis of their pharmacokinetic characteristics will be needed.
D002330:Carmustine / Q000627:therapeutic use; D006801:Humans; D007700:Kinetics; D008130:Lomustine / Q000627:therapeutic use; D009369:Neoplasms / Q000188:drug therapy; D015376:Nimustine; D009607:Nitrosourea Compounds / Q000378:metabolism* / Q000494:pharmacology / Q000627:therapeutic use; D012673:Semustine / Q000627:therapeutic use; D012995:Solubility; D013311:Streptozocin / Q000031:analogs & derivatives / Q000627:therapeutic use
D009607:Nitrosourea Compounds; D015376:Nimustine; D012673:Semustine; C007028:chlorozotocin; D013311:Streptozocin; D008130:Lomustine; C020766:ranimustine; D002330:Carmustine